US equities
|
INTC
$63.83
▼-30.68%
AMZN
$237.81
▼-2.45%
NVDA
$201.78
▼-5.56%
MU
$866.92
▼-7.21%
SNDK
$1,129.08
▼-15.11%
GOOGL
$278.31
▼-1.94%
AMD
$496.30
▼-12.38%
SPCX
$136.09
▼-5.42%
INTC
$63.83
▼-30.68%
AMZN
$237.81
▼-2.45%
NVDA
$201.78
▼-5.56%
MU
$866.92
▼-7.21%
SNDK
$1,129.08
▼-15.11%
GOOGL
$278.31
▼-1.94%
AMD
$496.30
▼-12.38%
SPCX
$136.09
▼-5.42%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Tonix Pharmaceuticals Holding Corp. - Common Stock
(NQ:
TNXP
)
5.105
-0.175 (-3.31%)
Delayed Quote
Updated: 2:26 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tonix Pharmaceuticals Holding Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026
April 23, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
April 15, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data for Lyme Disease Candidate TNX-4800, Plans Phase 2 Study
March 31, 2026
Via
Investor Brand Network
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
↗
March 30, 2026
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from late...
Via
Benzinga
Topics
Regulatory Compliance
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4 and Full-Year 2025 Results, Highlights Launch of TONMYA(TM)
March 13, 2026
Via
Investor Brand Network
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026
From
Virtual Investor Conferences
Via
GlobeNewswire
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print
↗
March 13, 2026
Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.
Via
Stocktwits
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress
March 10, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets
March 06, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting
March 04, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting
March 04, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market
March 03, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences
February 25, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data for TONMYA(TM) in Fibromyalgia at Non-Opioid Pain Summit
January 30, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
January 06, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
January 06, 2026
Via
Investor Brand Network
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug
↗
December 29, 2025
The company also announced the pricing of a $20 million registered direct offering.
Via
Stocktwits
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Provides Update on TNX-4800 Lyme Disease Prophylaxis Program
December 29, 2025
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces $20 Million Registered Direct Offering with Point72
December 29, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Irina Ishak as General Counsel
December 09, 2025
Via
Investor Brand Network
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’
↗
November 18, 2025
Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.
Via
Stocktwits
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
December 04, 2025
From
BioMedWire
Via
GlobeNewswire
Why Did TNXP Stock Jump 10% Today?
↗
November 17, 2025
Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia.
Via
Stocktwits
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
↗
November 17, 2025
Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA.
Via
Benzinga
TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) Surges 77% on Q3 Earnings Beat and Key Drug Launch
↗
November 10, 2025
Tonix Pharmaceuticals stock surged 77% after Q3 earnings beat estimates and confirming the November launch of its new fibromyalgia drug, Tonmya.
Via
Chartmill
Topics
Earnings
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
November 10, 2025
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results...
Via
MarketMinute
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Trial
September 30, 2025
Via
Investor Brand Network
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
August 19, 2025
Via
Benzinga
What's going on in today's session
↗
August 18, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
